Skip to content

Comparison of the Gastric Acid Suppressive Effects of Esomeprazole and Generic Omeprazole

Comparison of the Gastric Acid Suppressive Effects of Esomeprazole and Generic Omeprazole

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00542347
Enrollment
20
Registered
2007-10-11
Start date
2007-09-30
Completion date
2018-07-31
Last updated
2018-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Acid

Keywords

gastric acid, proton pump inhibitors, omeprazole, esomeprazole

Brief summary

Proton pump inhibitors (PPI) are used to decrease stomach acid secretion. A generic form of omeprazole, one of the PPIs, is on the market. With cheaper than brand name PPIs, it is unclear whether generic omeprazole is as effective clinically. This study compares generic omeprazole with half-dose esomeprazole, the strongest brand name PPI. The half-dose esomeprazole is in fact cheaper than generic omeprazole. Healthy volunteers will take each medication in turn for 7 days and their stomach acid will be measured while taking each medication. We hypothesize that half-dose esomeprazole is better at suppressing stomach acid than generic omeprazole.

Interventions

DRUGEsomeprazole first

* esomeprazole 20mg po once per day for 7 days * 24hr pH study on day 7 * followed by washout for 7 days * generic omeprazole 20mg po once per day for 7 days * 24hr pH study on day 7

DRUGGeneric omeprazole first

* generic omeprazole 20mg po once per day for 7 days * 24hr pH study on day 7 * followed by washout for 7 days * esomeprazole 20mg po once per day for 7 days * 24hr pH study on day 7

Sponsors

Canadian Institutes of Health Research (CIHR)
CollaboratorOTHER_GOV
Queen's University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* healthy, non-smoking volunteers older than 18 years of age

Exclusion criteria

* history of gastrointestinal disease * known infection * previous eradication of Helicobacter pylori * any prescription or over the counter antacid medication * pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
Median intragastric pH and percentage of time that intragastric pH is above 424 hours

Secondary

MeasureTime frame
Nocturnal acid breakthrough, defined as at least 60 continuous minutes of intragastric pH below 4 occurring between 10pm and 6 am and adverse events24 hours

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026